Amplius Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Amplius Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29	Closed	–	–	569
2021 Q4	$0	Buy	+29	New	+$68	﹤0.01%	971

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amplius Wealth Advisors's LCTX Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 29 shares.

Amplius Wealth Advisors first reported a position in LCTX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

Amplius Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
Amplius Wealth Advisors sold 29 Lineage Cell Therapeutics shares in Q1 2022.
Amplius Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 1 quarter.
Amplius Wealth Advisors's Lineage Cell Therapeutics position peaked at $0 in Q4 2021.
110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.